

2017 CABA INVESTMENT & ENTREPRENEURSHIP SYMPOSIUM

Saturday, September 30th, 2017 (8:30 AM – 5:30 PM)

Conference Center at Waltham Woods, 860 Winter Street, Waltham, MA 02451

- 08:30 Registration / Continental Breakfast (**Foyer**)
- 09:00 Opening Remarks from the Chair (**Auditorium**)
Ben Yibin Wei, Ph.D., MBA, Director, BD APAC, **PerkinElmer**
Executive Member, Chinese-American BioMedical Association (CABA)
- 09:05 Introduction of Chinese-American BioMedical Association (CABA)
Kevin Fang, Ph.D., Sr. Director, **Sunovion**
President, Chinese-American BioMedical Association (CABA)
- 09:15 ~ 15:30 Private 1-on-1 Sessions between Investors and Startup Companies (**Berkshire Room**)
- 09:15 ~ 10:35 **Session I: Entrepreneurship in Today's Biotech Industry (Auditorium)**
Session Chair/Moderator, **Lan Cao**, Ph.D., **CRISPR Therapeutics**
Biotech has been cultivating a hotbed of entrepreneurs. Biotech is not only a thriving industry with a wealth of possibilities, also it allows daring entrepreneurs to leave their stamp on world problems. Helping improve surgery, develop cures, or vaccinate against deadly diseases. What makes a biotech entrepreneur? In this session, four successful biotech entrepreneurs will share their personal stories about how they started from scratch and built companies that are helping the lives of patients.
- 09:15 *Rules of the Road – Biotechnology Entrepreneurship*
David Lucchino, MBA
Co-founder, President and CEO, **Frequency Therapeutics**
Incoming Chairman, Board of Directors, **Massachusetts Biotechnology Council**
Boston has been ranked #1 as the cluster for early stage biotech companies for several years. The inescapable gravity of biotech's key clusters: the great consolidation of talent, capital, and returns has made Boston one of the most attractive places for biotech entrepreneurs. Mr. Lucchino will share his experience of establishing several biotech companies in Boston, and his insights as the incoming BoD Chairman of the MassBio.
- 09:35 *Jacobio, a Novel Accelerator Model for Biotech Start-ups*
Yinxiang Wang, Ph.D., Founder and Chairman, **Beijing Jacobio Pharmaceuticals**
Dr. Wang, former CEO/Co-founder of Betta Pharmaceuticals, will tell us about his new startup, Jacobio, an innovative approach to help scientists and entrepreneurs. With novel ideas, even without solid research results, a scientist can also get angel investment, laboratory platform, and even R&D team support in Dr. Wang's Jacobio.
- 09:55 *Building a Biotech Company in China — Personal Experience*
Yuele Shen, Ph.D., Founder & CEO, **Beijing Biocytogen Co. Ltd.**

Many overseas Chinese scholars have dreams of building a biotech company. How to start a company in China, how to collaborate with VC's, and how to expand your business? Dr. Shen will tell his personal experiences and observations in China.

10:15

Building a Medical Device Start-up Company in China
Yu Li, MBA., Co-founder, Bowing Medical

The medical device market in China has excellent growth potential. Mr. Li will share his experience of building a startup with medical diagnostic imaging CT products in China.

10:35

Coffee Break (**Foyer**)

10:50 ~ 11:50

Session II: Investors' Perspective on Biotech Investment and M&A (Auditorium)
Session Chair/Moderator: **Youxin Zhang, Ph.D., Navigant**

Surging innovations in biotech segment, especially in the fields of oncology treatment, have attracted countless investors. Success stories, like Betta Pharmaceuticals and Biogen, create a promising vision of bio-startups and encourage talented individuals in biopharmaceutical companies to chase their entrepreneurial dream in China. How to see the potential value of innovations and startups? Welcome to this session and hear more from three investors, with diversified background in industry, venture capital, and startups and investment firm.

10:50

Crossing Barriers in Cross-border Investment
Yining Zhao, Ph.D., Venture Partner, Lilly Asia Ventures

With the increasing interests and influx of capital from China into US/EU biotech market, cross-border investment has become an emerging trend. This presentation will share some deep insights into this new investment paradigm from deal sourcing, structural building to post-deal management, and trying to unveil the feasibilities, complexity and pitfalls of the business model in the real world scenarios.

11:10

Everest Medicines: Building a Partner of Choice in China
Sean Wuxiong Cao, Ph.D., MBA, Managing Director, C-Bridge Capital, President and Interim CEO at Everest Medicines

Access to innovative medicines in China currently lags behind that in the United States, with nearly half of all drugs approved by the US Food and Drug Administration (FDA) between 2012 and 2017 still waiting to start the regulatory process in China. But ongoing reforms to China's regulatory environment are expected to accelerate development and approval times for imported innovative drugs by 2–5 years, heralding a new era of opportunity for the pharmaceutical industry.

11:30

Recent Acquisition Deals for Cancer Immunotherapy Companies
Han Ying, Ph.D., CSO, Sanpower Group; Global Strategic Consultant, Dendreon

Recently there have been several acquisition deals in the immuno-oncology (IO) field: Dendreon, with FDA-approved cellular immunotherapy for prostate cancer, was acquired for \$819.9 million in cash, by the Sanpower Group in China. Kite Pharmaceutical, with its to-be-approved CAR-T product, was acquired by Gilead Science for \$11.9 billion. Dr. Ying will share with us his insights on these deals in the IO field and future prospects.

11:50

Lunch Break (Dining Room) and Exhibitor Show (Foyer)

13:00 ~ 14:40

Session III: From Entry to Exit: What It Takes to Create a Viable Start-up (Auditorium)

The world is awash in cool new tech startups, with huge winners achieving massive scale, there is always enthusiasm in the biotech world to create the next big one. How to overcome the barriers to entry and how to make the right exit strategy is of course the billion-dollar question for startup companies. We hope experiences from the following success stories may shine some light on your road to entrepreneurship.

Session chair, **Bo Ying**, Ph.D. Director, Formulation and Drug Product Development, **Trucode Gene Repair Inc.**

Moderator: **Jun Wang**, Ph.D., VP of Discovery Biology, **Shanghai Medicilon Inc.**

13:00

From Start-up to IPO

Jun Wang, Ph.D., VP of Discovery Biology, **Shanghai Medicilon Inc.**

When Medicilon was founded in 2004, most of the startup funds were from Dr. Chunlin Chen's family. Now Medicilon has grown into a leading international CRO with targeted revenue of 100 million RMB in 2018. I would like to share with you our story of "A CRO company's route to going public in China".

13:20

How a Protein Company Becomes a Great Partner

Mike Yiding Chen, CEO, **Acrobiosystems**

Starting with the basic service and conquering all the difficulties— see how Acro has been growing and becoming a great partner to help the whole pharmaceutical community.

13:40

The Early Investment Opportunities for Biomedical Care in China

Feng Li, Founding Partner, **FreeS Fund**

Currently more than 80% of the national social health insurance expenditures go toward the purchase of imported drugs and supplies for major diseases. The gap between China's current domestic medical resources and supply is apparent. It is an urgent priority to leverage the potential cost savings on core drugs to reduce the absolute as well as relative contribution to healthcare expense. Therefore, it may be a great opportunity for early-stage investors to review new drug research and development in the domestic industry.

14:00

From Seed to Exit in 15 Months: the Delinia Story

Lijun Wu, Ph.D., Entrepreneur-In-Residence, **Atlas Venture**

I will focus this presentation on my most recent experience working at Delinia, a virtual start-up company. Delinia was funded by Atlas and Sofinnova in late 2015 and had \$35M seed and series A financing. In early 2017, ~15 months after the seed round, Delinia was acquired by Celgene for \$775M including \$300M upfront payment.

14:20

Session IV: Panel Discussion

**All-things-Considered for Biomedical Entrepreneurship and Investment:
Technology, Funding, and Legal Issues**

Moderator: **Jian Shao**, MBA, Sr. Director, BD & Investment, **Simcere of America, Inc.**

Biomedical Entrepreneurship is comprehensive and systematic endeavor, which includes market, capital, science, technology, operation, strategy, legal and accounting issues etc. There are many pitfalls as well as solutions. In this panel discussion, blue ribbon speakers with first-hand experience will share their thoughts and lessons learned.

Jiawen Han, MD., Ph.D., Head of BD, New England, **Qilu Pharmaceutical**

Chong Xu, Ph.D., Senior Associate, **F-Prime Capital**

Jing Li, Ph.D., Senior Vice President, **Wuxi Biologics**

Weimin Tang, Ph.D., Executive Director, **Hengrui Therapeutics Inc.**

Chen Chen, Ph.D. J.D., **Cooley LLP**

Geoffrey Spolyar, J.D., **Cooley LLP**

15:30

Coffee Break (**Foyer**)

15:50

Startup Pitch Competition (**Auditorium**)

16:50

CABA High School Student Research Award & Startup Pitch Award (**Auditorium**)
Susan Qu, Ph.D., MBA, **Sanofi Genzyme**
Cindy Yang, MBA, **Biogen**

17:30

Closing Remarks (**Auditorium**)

18:00 ~ 19:30

Cocktail Reception (Berkshire Room; Ticket sold separately)